oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
See also separate articles Migraine and Migraine Management.
Migraine prophylaxis may be underused. This may be because of patient resistance in the face of unwanted side-effects, but may also be because GPs are less experienced in the use of prophylactic drugs. It may be appropriate to offer referral when control of migraine is unsatisfactory and expertise in migraine prophylaxis is needed. However, it is often appropriate to manage prophylaxis in general practice. When successful, it is very beneficial to patients' quality of life. 50% of patients will have fewer migraines with preventative medication.
Aim of migraine management and prophylaxis
Migraine cannot be cured and the aim, shared with the patient, is to minimise the impact of the illness on the patient's life and lifestyle. The aim of prophylaxis is to reduce the number of migraine attacks.
Indications for prophylaxis
British Association for the Study of Headache (BASH) guidelines state that prophylaxis should be used when symptoms are inadequately controlled with acute prescriptions, or the frequency of attacks is leading to overuse of acute medicines.
Prodigy suggests that:
- Frequent attacks are two or more attacks per month that produce disability lasting for three days or more.
- Medication overuse is a risk when medication is used on more than two days per week on a regular basis. Overuse needs to be addressed before further treatment can begin.
- Prophylaxis should be used when standard analgesia and triptans are either contra-indicated or ineffective.
There has been speculation that timely use of prophylactic medication may prevent transformation of migraine to a chronic and more disabling form of migraine.
Uncommon types of migraine, such as hemiplegic migraine, or migraine with prolonged aura, should be seen by a specialist for appropriate management.
Choice of drug for migraine prophylaxis
A large number of drugs have been suggested but selection can be made according to:
- Efficacy and strength of evidence.
- The effect on other conditions the patient might have.
- Concordance issues, eg once-daily dosing improves compliance.
Most drugs are started at a low dose and titrated upwards to avoid adverse effects. Unfortunately, this can delay the onset of effect and adversely affect compliance. In general they should be tried for at least four weeks and, if effective, continued for 4-6 months before tapering off over 2-3 weeks to establish continued need. The following guide to first-, second- and third-line drugs is adapted from BASH and Prodigy guidance.
First-line prophylactic drugs
- Beta-blockers. In theory, the ideal beta-blocker for use in migraine should be hydrophilic and cardioselective so as to produce fewer side-effects, and have no sympathomimetic activity, so as to be more effective. Their use is limited by interactions and contra-indications.
- Atenolol 25-100 mg bd is cardioselective, hydrophilic and has no intrinsic sympathomimetic activity, but is unlicensed. BASH suggests it is to be preferred over the others, currently.
- Metoprolol 50-100 mg bd is cardioselective.
- Propranolol LA 80 mg od to 160 mg bd. Good supporting evidence for efficacy, but not cardioselective and often requires two doses daily.
- Bisoprolol 5-10 mg od may be ultimately the best but evidence is needed to establish efficacy.
- Timolol and nadolol are listed in the British National Formulary (BNF) too as possible alternatives.
- Amitriptyline. A dose of 10-150 mg daily 1-2 hours before bedtime, especially when:
- Chronic pain co-exists
- Insomnia co-exists
- Depression co-exists
Second-line prophylactic drugs
- Topiramate 25 mg od-50 mg bd. This is licensed and efficacy has been demonstrated.
- Sodium valproate 300-1000 mg bd. There is evidence for efficacy but it is unlicensed for this purpose. It is not safe in pregnancy but can be used with hormonal contraceptives.
Third-line prophylactic drugs
Pizotifen 1.5 mg daily has been used for a long time but evidence of efficacy is limited and certainly there is no justification for higher doses. Feverfew, a herbal remedy, has long been reputed to prevent migraine attacks but with little evidence to support its use.
Botulinum toxin injected into pericranial locations at three-monthly intervals has evidence of efficacy and is now recommended by NICE with the following criteria:
- if you have chronic migraine (that is, you have headaches on at least 15 days each month, with migraine on at least 8 of these days); and
- you have already tried at least three different medicine treatments to prevent your chronic migraine headaches, but these have not worked; and
- you are not taking too many painkillers or using them too often.
Also, treatment should be stopped if:
- the number of days you have a chronic migraine headache each month hasn’t reduced by at least 30% after two courses of botulinum toxin type A treatment; or
- your chronic migraine changes to episodic migraine (that is, you have fewer than 15 days with headaches each month) for three months in a row.
A variety of other drugs has been suggested but limited evidence for efficacy and potentially serious side-effects leads Prodigy to suggest these are for use by specialists only. Examples are gabapentin, clonidine, methysergide, selective serotonin reuptake inhibitors (SSRIs), verapamil, angiotensin-II receptor antagonists and a variety of anti-epileptics.
Combinations have also been suggested but the merits and efficacy of this approach are unproven.
Prophylaxis for hormone-related migraine
- Accurate diagnosis to treat this successfully is essential. This should be confirmed with diary evidence to show migraine without aura occurring regularly within up to two days of onset of menstruation and at no other time over three months.
- Mefenamic acid 500 mg qds as first-line if menorrhagia and/or dysmenorrhoea co-exist, taken at the onset of menstruation and continued prophylactically until the last day of bleeding.
- Oestrogen supplements alone can be given, if the patient is still menstruating and has an intact uterus. Transdermal oestrogen 100 micrograms is recommended starting three days before onset of menses and continued for seven days. If this dose is effective but poorly tolerated, 50 micrograms can be tried.
Progestogen-only methods (that inhibit the ovarian cycle) may also be used if contraception is also required. Cerazette®, Nexplanon® or depot medroxyprogesterone acetate are all suggested.
Migraine in pregnancy and lactation
Often migraine improves during pregnancy and prophylaxis is not required. Propranolol and amitriptyline have the best evidence for safety and efficacy but drugs should be avoided if possible.
Further reading & references
- Treatment guidelines for migraine, Migraine In Primary Care Advisors (2004)
- Goadsby PJ; Recent advances in the diagnosis and management of migraine; BMJ. 2006 Jan 7;332(7532):25-9.
- Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache; British Association for the Study of Headache - BASH (2010)
- Migraine; NICE CKS, December 2008
- Loder E, Biondi D; General principles of migraine management: the changing role of prevention.; Headache. 2005 Apr;45 Suppl 1:S33-47.
- Cady R, Schreiber C; Botulinum toxin type A as migraine preventive treatment in patients previously Headache. 2008 Jun;48(6):900-13. Epub 2007 Nov 28.
- Diamond M, Dahlof C, Papadopoulos G, et al; Topiramate improves health-related quality of life when used to prevent migraine.; Headache. 2005 Sep;45(8):1023-30.
- Migraine (chronic) - botulinum toxin type A, NICE Technology Appraisal Guideline (June 2012)
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Richard Draper||Current Version: Dr Tim Kenny||Peer Reviewer: Prof Cathy Jackson|
|Last Checked: 31/08/2012||Document ID: 239 Version: 8||© EMIS|